Steven Adelsheim
Clinical Professor, Psychiatry and Behavioral Sciences
Bio
Steven Adelsheim, MD is a child/adolescent and adult psychiatrist who works to support community behavioral health partnerships locally, regionally, at the state level and nationally. He is the Director of the Stanford Center for Youth Mental Health and Wellbeing in the Department of Psychiatry. Dr. Adelsheim has partnered in developing statewide mental health policy and systems, including those focused on school mental health, telebehavioral health, tribal behavioral health programs, and suicide prevention. For many years Dr. Adelsheim has been developing and implementing early detection/intervention programs for young people in school-based and primary care settings, including programs for depression, anxiety, prodromal symptoms of psychosis, and first episodes of psychosis. Dr. Adelsheim is also involved in the implementation of integrated behavioral health care models in primary care settings as well as the use of media to decrease stigma surrounding mental health issues. He is currently leading the US effort to implement the headspace model of mental health early intervention for young people ages 12-25 based in Australia. Dr. Adelsheim also leads the national clinical network for early psychosis programs called PEPPNET.
Clinical Focus
- Child and Adolescent Psychiatry
Academic Appointments
-
Clinical Professor, Psychiatry and Behavioral Sciences
Administrative Appointments
-
Director, Stanford Center for Youth Mental Health and Wellbeing; Stanford Department of Psychiatry (2015 - Present)
-
Associate Chair for Community Partnerships, Stanford Department of Psychiatry and Behavioral Sciences (2013 - Present)
Honors & Awards
-
Outstanding Faculty Award, Graduating Child Psychiatry Trainees; Stanford department of psychiatry and Behavioral Sciences (2016)
-
Chair’s Award for Community Commitment and Engagement;, Stanford Department of Psychiatry and Behavioral Sciences (2014)
-
Sidney Berman Award for School-Based Study and Treatment of Learning Disorders and Mental Illness, American Academy of Child and Adolescent Psychiatry (2012)
-
NAMI Exemplary Psychiatrist Award, National Alliance on Mental Illness (2009)
-
Agnes Purcell McGavin Award for Prevention, American Psychiatric Association (2006)
-
Bronze World Medal; “Not in My Family”; Associate Producer, New York Festival (2006)
-
Best Documentary and Best Writing-Programs, Documentaries or Magazines, “Coming Back”, Rocky Mountain SW Chapter; National Academy of Television Arts and Sciences; Clinical Editor (2005)
-
Irving Phillips Award for Prevention, American Academy of Child and Adolescent Psychiatry (2005)
-
Juanita Evans Memorial Award, Center for School Mental Health, University of Maryland School of Medicine (2003)
-
"Marketer of the Year” Award; “Childhood Revealed, New Mexico 2001”, New Mexico Chapter of the American Marketing Association (2002)
-
Norbert and Charlotte Rieger Service Program Award for Excellence, American Academy of Child and Adolescent Psychiatry (1999)
-
Highland Human Services Collaborative Award for Exemplary Dedication, Highland Human Services Collaborative; New Mexico Advocates for Children and Families (1998)
Boards, Advisory Committees, Professional Organizations
-
Consultant, Council on Children, Adolescents & Families, American Psychiatric Association (2015 - 2023)
-
Member, American College of Psychiatrists (2013 - Present)
-
Member, Adolescent Committee, American Academy of Child and Adolescent Psychiatry (2013 - 2018)
-
Member, New Mexico Native American Suicide Prevention Workgroup and Clearinghouse (2011 - 2013)
-
Councilor at Large, American Academy of Child and Adolescent Psychiatry (2010 - 2013)
-
National Advisory Board, Robert Wood Johnson Foundation Local Funding Partners (2009 - 2015)
-
Member, Committee on Telepsychiatry, American Academy of Child and Adolescent Psychiatry (2009 - 2011)
-
National Advisory Board, Robert Wood Johnson Foundation Early Detection and Intervention for the Prevention of Psychosis Program (2008 - 2010)
-
Member, New Mexico State Workgroup on Child Psychopharmacology (2007 - 2013)
-
President, New Mexico Council on Child and Adolescent Psychiatry (2007 - 2008)
-
National Advisory Committee, Center for School Mental Health, University of Maryland Department of Psychiatry (2005 - Present)
-
Chair, New Mexico Child Fatality Review Suicide Review Panel (2005 - 2010)
-
Commissioner, New Mexico Telehealth Commission (2005 - 2009)
-
Member, New Mexico Governor's Task Force on Compulsive Gambling (2005 - 2009)
-
Convener and Coordinator, New Mexico Governor's Task Force on Youth Suicide Prevention (2004 - 2005)
-
Co-Chair, Committee on Schools, American Academy of Child and Adolescent Psychiatry (2003 - 2010)
-
Associate Member, John D. and Katherine T. MacArthur Foundation Network on Mental Health Policy Research (2003 - 2009)
-
Member, New Mexico State Medicaid Advisory Committee (2003 - 2008)
Professional Education
-
Board Certification: American Board of Psychiatry and Neurology, Psychiatry (1991)
-
Board Certification: American Board of Psychiatry and Neurology, Child and Adolescent Psychiatry (1991)
-
Fellowship: University of New Mexico School of Medicine (1990) NM
-
Residency: University of New Mexico School of Medicine (1988) NM
-
Medical Education: University of Cincinnati College of Medicine (1985) OH
-
Board Certification, American Board of Psychiatry and Neurology, Child and Adolescent Psychiatry (1991)
-
Board Certification, American Board of Psychiatry and Neurology, General Psychiatry (1991)
-
Fellowship, University of New Mexico Health Sciences Center, Child and Adolescent Psychiatry (1990)
-
Residency, University of New Mexico health Sciences Center, General Psychiatry (1988)
-
MD, University of Cincinnati College of Medicine (1985)
-
BA, Harvard College, Psychology and Social Relations (1979)
2024-25 Courses
-
Independent Studies (7)
- Community Health and Prevention Research Master's Thesis Writing
CHPR 399 (Aut, Win, Spr, Sum) - Curricular Practical Training and Internship
CHPR 290 (Aut, Win, Spr, Sum) - Directed Reading in Psychiatry
PSYC 299 (Aut, Win, Spr, Sum) - Graduate Research
PSYC 399 (Aut, Win, Spr, Sum) - Medical Scholars Research
PSYC 370 (Aut, Win, Spr, Sum) - Teaching in Psychiatry
PSYC 290 (Aut, Win, Spr, Sum) - Undergraduate Research, Independent Study, or Directed Reading
PSYC 199 (Aut, Win, Spr, Sum)
- Community Health and Prevention Research Master's Thesis Writing
All Publications
-
The Lancet Psychiatry Commission on youth mental health.
The lancet. Psychiatry
2024; 11 (9): 731-774
View details for DOI 10.1016/S2215-0366(24)00163-9
View details for PubMedID 39147461
-
THE STANFORD CHILD AND ADOLESCENT MENTAL HEALTH ECHO FOR NATIVE AMERICAN YOUTH: EXPANDING CAPACITY IN SUPPORT OF NATIVE YOUTH AND FAMILIES
ELSEVIER SCIENCE INC. 2023: S394
View details for DOI 10.1016/j.jaac.2023.07.877
View details for Web of Science ID 001098830401585
-
Recreational cannabis use over time in individuals at clinical high risk for psychosis: Lack of associations with symptom, neurocognitive, functioning, and treatment patterns.
Psychiatry research
2023; 328: 115420
Abstract
Recreational cannabis use has recently gained considerable interest as an environmental risk factor that triggers the onset of psychosis. To date, however, the evidence that cannabis is associated with negative outcomes in individuals at clinical high risk (CHR) for psychosis is inconsistent. The present study tracked cannabis usage over a 2-year period and examined its associations with clinical and neurocognitive outcomes, along with medication rates. CHR youth who continuously used cannabis had higher neurocognition and social functioning over time, and decreased medication usage, relative to non-users. Surprisingly, clinical symptoms improved over time despite the medication decreases.
View details for DOI 10.1016/j.psychres.2023.115420
View details for PubMedID 37657201
-
THE ALLCOVE YOUTH MENTAL HEALTH IMPERATIVE: DEVELOPING EARLY INTERVENTION MENTAL HEALTH PROGRAMS BY AND WITH YOUNG PEOPLE
ELSEVIER SCIENCE INC. 2022: S24
View details for DOI 10.1016/j.jaac.2022.07.831
View details for Web of Science ID 000873567900086
-
THE CHILD AND ADOLESCENT PSYCHIATRIST'S ROLE AFTER LOSS AND TRAGEDY: SUICIDE POSTVENTION AND PREVENTION AS A BEST PRACTICE MODEL
ELSEVIER SCIENCE INC. 2020: S51–S52
View details for DOI 10.1016/j.jaac.2020.07.219
View details for Web of Science ID 000579844100166
-
Lived experience perspectives on reducing the duration of untreated psychosis: the impact of stigma on accessing treatment
PSYCHOSIS-PSYCHOLOGICAL SOCIAL AND INTEGRATIVE APPROACHES
2020
View details for DOI 10.1080/17522439.2020.1754890
View details for Web of Science ID 000531980000001
-
SYSTEMS OF CARE IN FIRST EPISODE PSYCHOSIS
ELSEVIER SCIENCE INC. 2019: S87
View details for DOI 10.1016/j.jaac.2019.07.493
View details for Web of Science ID 000518857301052
-
FUNDING MODELS TO ENABLE IMPLEMENTATION OF INNOVATIVE INTERVENTIONS IN CHILD AND ADOLESCENT PSYCHIATRY
ELSEVIER SCIENCE INC. 2019: S23
View details for DOI 10.1016/j.jaac.2019.07.098
View details for Web of Science ID 000518857300079
-
Predicting psychosis risk using a specific measure of cognitive control: a 12-month longitudinal study.
Psychological medicine
2019: 1–10
Abstract
BACKGROUND: Identifying risk factors of individuals in a clinical-high-risk state for psychosis are vital to prevention and early intervention efforts. Among prodromal abnormalities, cognitive functioning has shown intermediate levels of impairment in CHR relative to first-episode psychosis and healthy controls, highlighting a potential role as a risk factor for transition to psychosis and other negative clinical outcomes. The current study used the AX-CPT, a brief 15-min computerized task, to determine whether cognitive control impairments in CHR at baseline could predict clinical status at 12-month follow-up.METHODS: Baseline AX-CPT data were obtained from 117 CHR individuals participating in two studies, the Early Detection, Intervention, and Prevention of Psychosis Program (EDIPPP) and the Understanding Early Psychosis Programs (EP) and used to predict clinical status at 12-month follow-up. At 12 months, 19 individuals converted to a first episode of psychosis (CHR-C), 52 remitted (CHR-R), and 46 had persistent sub-threshold symptoms (CHR-P). Binary logistic regression and multinomial logistic regression were used to test prediction models.RESULTS: Baseline AX-CPT performance (d-prime context) was less impaired in CHR-R compared to CHR-P and CHR-C patient groups. AX-CPT predictive validity was robust (0.723) for discriminating converters v. non-converters, and even greater (0.771) when predicting CHR three subgroups.CONCLUSIONS: These longitudinal outcome data indicate that cognitive control deficits as measured by AX-CPT d-prime context are a strong predictor of clinical outcome in CHR individuals. The AX-CPT is brief, easily implemented and cost-effective measure that may be valuable for large-scale prediction efforts.
View details for DOI 10.1017/S0033291719002332
View details for PubMedID 31507256
-
Baseline psychopathology and relationship to longitudinal functional outcome in attenuated and early first episode psychosis.
Schizophrenia research
2019
Abstract
BACKGROUND: As efforts intensify to intervene early among those at risk for psychosis, examination of the relationship between presenting psychopathology and long-term functional outcome may guide treatment decision-making and offer a means to prevent or reduce chronic disability.METHODS: Data were collected through the Early Detection and Intervention for the Prevention of Psychosis Program (EDIPPP), a multisite national trial testing the efficacy of an early intervention for youth at risk of developing psychosis. Participants were followed prospectively and completed comprehensive evaluations at 6, 12, and 24 months, including the Structured Interview for Prodromal Syndromes (SIPS) and the Global Social and Role Functioning Scales. The present analyses included 327 participants and examined the relationships between baseline symptoms and longitudinal global social and role functioning using a linear mixed modeling approach.RESULTS: Higher baseline negative symptoms and deteriorated thought process predicted worse social and role functioning in the follow-up period. The effect of negative symptoms on social functioning, however, was moderated by positive symptoms, and the relationship between positive symptoms and social functioning changed over time. Baseline positive symptoms, distress, and level of symptom severity were not predictors of either social or role functioning.CONCLUSIONS: Baseline negative symptoms and thought disorder appear to predict functional outcome for up to two years among adolescents and young adults at risk for psychosis. Developing effective interventions to target these symptoms may be critical to promote functional recovery among those experiencing attenuated symptoms or a first episode of psychosis.
View details for DOI 10.1016/j.schres.2019.07.048
View details for PubMedID 31395490
-
Growth of Early Intervention in Psychosis in the United States
INTERVENING EARLY IN PSYCHOSIS: A TEAM APPROACH
2019: 11–22
View details for Web of Science ID 000549765400003
-
Consumer and Family Perspectives on Reducing the Duration of Untreated Psychosis
WILEY. 2018: 62
View details for Web of Science ID 000444798900176
-
PSYCHOSIS AND PSYCHOTIC DISORDERS: PREDICTION AND PREVENTION
ELSEVIER SCIENCE INC. 2018: S76
View details for DOI 10.1016/j.jaac.2018.07.319
View details for Web of Science ID 000544087500257
-
From the psychosis prodrome to the first-episode of psychosis: No evidence of a cognitive decline
JOURNAL OF PSYCHIATRIC RESEARCH
2018; 96: 231–38
Abstract
Cognitive deficits have an important role in the neurodevelopment of schizophrenia and other psychotic disorders. However, there is a continuing debate as to whether cognitive impairments in the psychosis prodrome are stable predictors of eventual psychosis or undergo a decline due to the onset of psychosis. In the present study, to determine how cognition changes as illness emerges, we examined baseline neurocognitive performance in a large sample of helping-seeking youth ranging in clinical state from low-risk for psychosis through individuals at clinical high-risk (CHR) for illness to early first-episode patients (EFEP). At baseline, the MATRICS Cognitive Consensus battery was administered to 322 individuals (205 CHRs, 28 EFEPs, and 89 help-seeking controls, HSC) that were part of the larger Early Detection, Intervention and Prevention of Psychosis Program study. CHR individuals were further divided into those who did (CHR-T; n = 12, 6.8%) and did not (CHR-NT, n = 163) convert to psychosis over follow-up (Mean = 99.20 weeks, SD = 21.54). ANCOVAs revealed that there were significant overall group differences (CHR, EFEP, HSC) in processing speed, verbal learning, and overall neurocognition, relative to healthy controls (CNTL). In addition, the CHR-NTs performed similarly to the HSC group, with mild to moderate cognitive deficits relative to the CTRL group. The CHR-Ts mirrored the EFEP group, with large deficits in processing speed, working memory, attention/vigilance, and verbal learning (>1 SD below CNTLs). Interestingly, only verbal learning impairments predicted transition to psychosis, when adjusting for age, education, symptoms, antipsychotic medication, and neurocognitive performance in the other domains. Our findings suggest that large neurocognitive deficits are present prior to illness onset and represent vulnerability markers for psychosis. The results of this study further reinforce that verbal learning should be specifically targeted for preventive intervention for psychosis.
View details for PubMedID 29121595
-
EARLY PSYCHOSIS CLINICAL IMPLEMENTATION FROM A CHILD/ADOLESCENT PERSPECTIVE: COMMUNITY AND NATIONAL DEVELOPMENTS
ELSEVIER SCIENCE INC. 2017: S341
View details for DOI 10.1016/j.jaac.2017.07.721
View details for Web of Science ID 000544086202268
-
BASELINE PSYCHOPATHOLOGY AS PREDICTORS OF FUNCTIONAL OUTCOME IN ATTENUATED AND EARLY FIRST EPISODE PSYCHOSIS
OXFORD UNIV PRESS. 2017: S256–S257
View details for Web of Science ID 000397126200689
-
Factor analysis of the Scale of Prodromal Symptoms: data from the Early Detection and Intervention for the Prevention of Psychosis Program
EARLY INTERVENTION IN PSYCHIATRY
2017; 11 (1): 14-22
Abstract
The Scale of Prodromal Symptoms (SOPS) was developed to identify individuals experiencing early signs of psychosis, a critical first step towards early intervention. Preliminary dimension reduction analyses suggested that psychosis-risk symptoms may deviate from the traditional symptom structure of schizophrenia, but findings have been inconsistent. This study investigated the phenomenology of psychosis risk symptoms in a large sample from a multi-site, national study using rigorous factor analysis procedure.Participants were 334 help-seeking youth (age: 17.0 ± 3.3) from the Early Detection and Intervention for the Prevention of Psychosis Program, consisting of 203 participants at clinically higher risk (sum of P scores ≥ 7), 87 with clinically lower risk (sum of P scores < 7) and 44 in very early first-episode psychosis (<30 days of positive symptoms). Baseline SOPS data were subjected to principal axis factoring (PAF), estimating factors based on shared variance, with Oblimin rotation.PAF yielded four latent factors explaining 36.1% of total variance: positive symptoms; distress; negative symptoms; and deteriorated thought process. They showed reasonable internal consistency and good convergence validity, and were not orthogonal.The empirical factors of the SOPS showed similarities and notable differences compared with the existing SOPS structure. Regrouping the symptoms based on the empirical symptom dimensions may improve the diagnostic validity of the SOPS. Relative prominence of the factors and symptom frequency support early identification strategies focusing on positive symptoms and distress. Future investigation of long-term functional implications of these symptom factors may further inform intervention strategies.
View details for DOI 10.1111/eip.12209
View details for Web of Science ID 000397107400002
-
CHILD AND ADOLESCENT PSYCHOSIS
HANDBOOK OF CHILDHOOD BEHAVIORAL ISSUES: EVIDENCE-BASED APPROACHES TO PREVENTION AND TREATMENT, 2ND EDITION
2017: 319-335
View details for Web of Science ID 000460967900019
-
Personalized Prediction of Psychosis: External Validation of the NAPLS-2 Psychosis Risk Calculator With the EDIPPP Project
AMERICAN JOURNAL OF PSYCHIATRY
2016; 173 (10): 989-996
Abstract
As part of the second phase of the North American Prodrome Longitudinal Study (NAPLS-2), Cannon and colleagues report, concurrently with the present article, on a risk calculator for the individualized prediction of a psychotic disorder in a 2-year period. The present study represents an external validation of the NAPLS-2 psychosis risk calculator using an independent sample of patients at clinical high risk for psychosis collected as part of the Early Detection, Intervention, and Prevention of Psychosis Program (EDIPPP).Of the total EDIPPP sample of 210 subjects rated as being at clinical high risk based on the Structured Interview for Prodromal Syndromes, 176 had at least one follow-up assessment and were included in the construction of a new prediction model with six predictor variables in the NAPLS-2 psychosis risk calculator (unusual thoughts and suspiciousness, symbol coding test performance, verbal learning test performance, decline in social functioning, baseline age, and family history). Discrimination performance was assessed with the area under the receiver operating characteristic curve (AUC). The NAPLS-2 risk calculator was then used to generate a psychosis risk estimate for each case in the external validation sample.The external validation model showed good discrimination, with an AUC of 0.790 (95% CI=0.644-0.937). In addition, the personalized risk generated by the risk calculator provided a solid estimation of the actual conversion outcome in the validation sample.Two independent samples of clinical high-risk patients converge to validate the NAPLS-2 psychosis risk calculator. This prediction calculator represents a meaningful step toward early intervention and the personalized treatment of psychotic disorders.
View details for DOI 10.1176/appi.ajp.2016.15121565
View details for Web of Science ID 000384158400010
View details for PubMedID 27363511
View details for PubMedCentralID PMC5048503
-
Implementation of a National Early Psychosis Clinical Support Program in the United States: The Prodrome and Early Psychosis Program Network (PEPPNET)
WILEY-BLACKWELL. 2016: 23
View details for Web of Science ID 000385582800062
-
Creating a National Early Psychosis Clinical Support Program in the United States: The Development of the Prodrome and Early Psychosis Program Network (PEPPNET)
WILEY-BLACKWELL. 2016: 99
View details for Web of Science ID 000385582800295
-
Early Detection, Intervention and Prevention of Psychosis Program: Community Outreach and Early Identification at Six US Sites
PSYCHIATRIC SERVICES
2016; 67 (5): 510-516
Abstract
This study assessed the effects of a community outreach and education model implemented as part of the Early Detection, Intervention and Prevention of Psychosis Program (EDIPPP), a national multisite study in six U.S. regions.EDIPPP's model was designed to generate rapid referrals of youths at clinical high risk of psychosis by creating a network of professionals and community members trained to identify signs of early psychosis. Qualitative and quantitative data were gathered through an evaluation of outreach efforts at five sites over a two-year period and through interviews with staff at all six sites. All outreach activities to groups (educational, medical, and mental health professionals; community groups; media; youth and parent groups; and multicultural communities) were counted for the six sites to determine correlations with total referrals and enrollments.During the study period (May 2007-May 2010), 848 formal presentations were made to 22,840 attendees and 145 informal presentations were made to 11,528 attendees at all six sites. These presentations led to 1,652 phone referrals. A total of 520 (31%) of these individuals were offered in-person orientation, and 392 (75%) of those were assessed for eligibility. A total of 337 individuals (86% of those assessed) met criteria for assignment to the EDIPPP study.EDIPPP's outreach and education model demonstrated the effectiveness of following a protocol-defined outreach strategy combined with flexibility to reach culturally diverse audiences or initially inaccessible systems. All EDIPPP sites yielded appropriate referrals of youths at risk of psychosis.
View details for DOI 10.1176/appi.ps.201300236
View details for Web of Science ID 000377779100012
View details for PubMedID 26766751
-
Clinical and functional outcomes after 2 years in the early detection and intervention for the prevention of psychosis multisite effectiveness trial.
Schizophrenia bulletin
2015; 41 (1): 30-43
Abstract
To test effectiveness of the Early Detection, Intervention, and Prevention of Psychosis Program in preventing the onset of severe psychosis and improving functioning in a national sample of at-risk youth.In a risk-based allocation study design, 337 youth (age 12-25) at risk of psychosis were assigned to treatment groups based on severity of positive symptoms. Those at clinically higher risk (CHR) or having an early first episode of psychosis (EFEP) were assigned to receive Family-aided Assertive Community Treatment (FACT); those at clinically lower risk (CLR) were assigned to receive community care. Between-groups differences on outcome variables were adjusted statistically according to regression-discontinuity procedures and evaluated using the Global Test Procedure that combined all symptom and functional measures.A total of 337 young people (mean age: 16.6) were assigned to the treatment group (CHR + EFEP, n = 250) or comparison group (CLR, n = 87). On the primary variable, positive symptoms, after 2 years FACT, were superior to community care (2 df, p < .0001) for both CHR (p = .0034) and EFEP (p < .0001) subgroups. Rates of conversion (6.3% CHR vs 2.3% CLR) and first negative event (25% CHR vs 22% CLR) were low but did not differ. FACT was superior in the Global Test (p = .0007; p = .024 for CHR and p = .0002 for EFEP, vs CLR) and in improvement in participation in work and school (p = .025).FACT is effective in improving positive, negative, disorganized and general symptoms, Global Assessment of Functioning, work and school participation and global outcome in youth at risk for, or experiencing very early, psychosis.
View details for DOI 10.1093/schbul/sbu108
View details for PubMedID 25065017
View details for PubMedCentralID PMC4266296
-
Factor analysis of the Scale of Prodromal Symptoms: data from the Early Detection and Intervention for the Prevention of Psychosis Program.
Early intervention in psychiatry
2014
Abstract
The Scale of Prodromal Symptoms (SOPS) was developed to identify individuals experiencing early signs of psychosis, a critical first step towards early intervention. Preliminary dimension reduction analyses suggested that psychosis-risk symptoms may deviate from the traditional symptom structure of schizophrenia, but findings have been inconsistent. This study investigated the phenomenology of psychosis risk symptoms in a large sample from a multi-site, national study using rigorous factor analysis procedure.Participants were 334 help-seeking youth (age: 17.0 ± 3.3) from the Early Detection and Intervention for the Prevention of Psychosis Program, consisting of 203 participants at clinically higher risk (sum of P scores ≥ 7), 87 with clinically lower risk (sum of P scores < 7) and 44 in very early first-episode psychosis (<30 days of positive symptoms). Baseline SOPS data were subjected to principal axis factoring (PAF), estimating factors based on shared variance, with Oblimin rotation.PAF yielded four latent factors explaining 36.1% of total variance: positive symptoms; distress; negative symptoms; and deteriorated thought process. They showed reasonable internal consistency and good convergence validity, and were not orthogonal.The empirical factors of the SOPS showed similarities and notable differences compared with the existing SOPS structure. Regrouping the symptoms based on the empirical symptom dimensions may improve the diagnostic validity of the SOPS. Relative prominence of the factors and symptom frequency support early identification strategies focusing on positive symptoms and distress. Future investigation of long-term functional implications of these symptom factors may further inform intervention strategies.
View details for DOI 10.1111/eip.12209
View details for PubMedID 25529847
-
From School Health to Integrated Health: Expanding Our Children's Public Mental Health System.
Academic psychiatry
2014; 38 (4): 405-408
Abstract
There is a substantial unmet need for mental health and substance abuse services in the USA. In 2009, the Institute of Medicine recommended increased early identification and intervention for young people with mental, emotional, and behavioral disorders. With the expansion of integrated models in primary care settings, we now have the chance to improve outcomes for young people with mental health conditions, just as we have by improving the early identification and treatment of other preventable and/or treatable conditions such as obesity, asthma, or HIV. This is a moment of great opportunity to fundamentally change how young people access mental health care in our country. Through strategic integration of care, we can increase access to care for those who would not seek out mental health services because of the stigma or inconvenience of reaching out to a mental health provider; we can identify those who need care earlier and reduce the impact of mental illness on individuals, family, and community through early identification and treatment; and we can purposefully embed integration into provider training programs for both primary care and mental health providers to ensure sustainability.
View details for DOI 10.1007/s40596-014-0174-z
View details for PubMedID 24912970